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ETB receptor protects the tubulointerstitium in experimental developed a model induced by the renal artery perfusion
thrombotic microangiopathy. of anti-glomerular endothelial cell antibody [1, 2]. This
Background. The characteristic features of thrombotic mi-
model demonstrates features similar to hemolytic uremiccroangiopathy (TMA) include glomerular and peritubular cap-
syndrome in humans, including glomerular and peritubu-illary endothelial cell injury with thrombus formation and sub-
sequent ischemic tubulointerstitial damage. The endothelin lar capillary endothelial cell injury with platelet accumu-
ETB receptor has been shown to mediate both endothelial cell lation and fibrin deposition, microangiopathic hemolysis,
proliferation and vasodilation, and we therefore hypothesized
mild thrombocytopenia, and renal failure [3, 4]. Whilethat blockade of this receptor might promote more severe
some glomerular and peritubular capillary repair occursinjury in this model.
Methods. TMA was induced in recently established trans- after the initial endothelial damage, this repair process is
genic rats that lack expression of ETB receptor in the kidney; not complete, and progressive tubulointerstitial damage
these animals were compared to control rats with TMA both
occurs. Our current study was designed to investigate ain the short-term (days 1 and 3) when acute glomerular injury
role of ETB receptor in the TMA model, because thiswas most manifest, and the long-term (day 17) when glomeruli
have recovered but tubulointerstitial injury is still present. Re- endothelin receptor is thought to modulate both endo-
nal damage was assessed by histological analysis and blood thelial cell proliferation and vascular dilation [reviewedurea nitrogen (BUN) measurements.
in 5–12].Results. No difference in the TMA model was observed be-
tween rats with and without ETB receptor on days 1 or 3. At Endothelins are a family of 21 amino acid peptides
day 17, however, rats without the ETB receptor showed more that include three distinct isoforms (ET-1, ET-2, and
severe tubulointerstitial injury compared with those with ETB ET-3). ET-1 acts as a paracrine/autocrine factor and isreceptor, which was associated with higher BUN levels. The
secreted by vascular endothelial cells abluminally wheretubulointerstitial damage was associated with a more severe
loss of peritubular capillaries. it can act on the smooth muscle cell [13]. In the kidney,
Conclusions. These findings suggest that the ETB receptor ET-1 is produced by glomerular epithelial cells, mesan-
may protect peritubular capillaries under the ischemic insult, gial cells, endothelial cells, and tubular cells [14–16].and serve a defensive role in the tubulointerstitium induced
These isopeptides show different biological activitiesby renal microvascular injury.
and bind to two subtypes of G protein-coupled receptors.
One is ETA receptor that shows a selective affinity for
ET-1, and the other is ETB receptor that shows a non-The hemolytic uremic syndrome and other related
thrombotic microangiopathy (TMA) are characterized selective affinity for all three isoforms. The ETB receptor
by injury to the renal microvascular endothelium. To is expressed in a variety of tissues, and ETB receptor
elucidate the pathophysiology of renal TMA, we recently stimulation exerts a variety of biological effects including
vasodilation and endothelial cell proliferation [17, 18].
Based on the actions of the ETB receptor, we hypothe-Key words: ischemia, endothelium, hemolytic-uremic syndrome, hyp-
sized that it may play a protective role in the kidney ofoxia, endothelin, renoprotection, progressive renal disease.
TMA. To investigate the role of ETB receptor in TMAReceived for publication October 8, 2001
model of rats, we employed recently established trans-and in revised form April 10, 2002
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METHODS with the periodic acid-Schiff (PAS) reagent and counter-
stained with hematoxylin. An indirect immunoperoxi-Experimental protocol and disease model
dase method was used as previously described [4] to
The renal TMA model was induced by the selective
identify the following antigens: renal microvascular en-perfusion of the right kidney through the superior mes-
dothelial cells with monoclonal antibody JG-12 (a gener-enteric artery with the purified goat anti-glomerular en-
ous gift from Dr. Dontcho Kerjaschki, Vienna, Austria)dothelial cell (GEN) antibody. The characteristics of the
[14]; monocyte-macrophages with antibody ED-1 (Bio-anti-GEN antibody and the technique of selective right
products for Science, Indianapolis, IN, USA); osteopon-renal artery perfusion were described previously [1].
tin with goat anti-osteopontin (OPN; 199; Ceci Giachelli,Briefly, the right kidney was perfused through the supe-
University of WA, Seattle, WA, USA), proliferating cellrior mesenteric artery with 0.2 mL saline, followed by
nuclear antigen (PCNA) with PC10 (Dako A/S, Glos-30 mg/kg body weight of anti-GEN IgG. Ischemic time
trop, Denmark), and platelets with monoclonal antibodywas less than six minutes in each rat.
PL-1 (generously provided by W.W. Baker, University ofIn the first set of experiments, the role of the ETB Groningen, Groningen, the Netherlands) [20]. Controlsreceptor was investigated in the TMA model at days 1
included omission of the primary antibody or substitu-and 3. Three groups of rats were studied. Group I was
tion with an irrelevant antibody of the same species andcomposed of spotting lethal rats rescued by the transgene
isotype.of the ETB receptor with a neuron-specific promoter
Tissue for immunofluorescence was embedded in(EDNRBsl rats; N  7). These rats show expression of
O.C.T. compound and snap-frozen in isopentane. FibrinETB receptor in a tissue-specific manner, with undetect-
was detected by staining with FITC-conjugated goat anti-able levels of ETB receptor in the kidney [19]. Group II
fibrinogen IgG (Cappel Laboratory, Durham, NC, USA).was composed of wild type Wistar-Imamichi rats (N 
Deposition of the pathogenic goat anti-GEN antibody7). Group III was composed of control EDNRBsl rats
was detected by biotinylated anti-goat IgG (Secondaryrats perfused with normal goat IgG (N 3). In these rats,
antibody; Dako Corp., Carpinteria, CA, USA), followedthe unperfused left kidney was removed for evaluation of
by incubation with Oregon green/Neutralite Avidinrenal function prior to closing the abdominal incision
(Molecular Probes Inc., Eugene, OR, USA).when the disease was induced by selective renal artery
Quantification was performed in a blinded manner onperfusion. Twenty-four hours after perfusion, a blood
30 randomly selected glomeruli per biopsy for each ofsample was obtained, and a survival renal biopsy of the
the following variables: glomerular thrombi was assessedperfused kidney was performed in all groups. Three days
by immunostaining with anti-fibrinogen, glomerular en-after induction of disease, a blood sample was obtained
dothelial cell loss by immunostaining for renal microvas-via a cardiac puncture, and a sacrificial biopsy was per-
cular endothelium with JG-12 antibody; and platelet ag-formed for histologic analysis.
gregation by PL-1 staining. For glomeruli thrombi andIn the second set of experiments, the role of the ETB
platelet infiltration, a semiquantitative scoring systemreceptor was investigated in the long term at day 17.
was used as follows: 0 normal; 1 0 to 25% of glomer-Three groups of rats were studied. Group IV was com-
ular area involved; 2  25 to 50% of glomerular tuftposed of EDNRBsl rats (N  12). Group V was com-
involved; 3  50 to 75% of tuft area involved; and 4 posed of wild-type Wistar-Imamichi rats (N  12).
75% of tuft area involved. A glomerular endothelialGroup VI was composed of control EDNRBsl rats per-
score was graded as follows: 0  0 to 25% glomerularfused with normal goat IgG (N 3). In these experimen-
tuft stains positive for endothelium; 1  25 to 50% posi-tal animals, the unperfused left kidney was removed at
tive; 3  50 to 75% positive; 4  75 to 100% positive.day 14 and rats were sacrificed at day 17.
The number of glomerular macrophages (ED-1 positive)All animal experimentation was conducted in accord
also was enumerated per glomerular cross section. Glo-with the Guide for Animal Experimentation, Faculty of
merular cross sections containing only a minor portionMedicine, University of Tokyo.
of the glomerular tuft (20 discrete capillary segments
Blood pressure measurement per cross section) were not utilized. Glomerular sclerosis
was assessed by periodic acid Schiff (PAS) staining, andSystolic blood pressure was measured in conscious,
was defined as segmental or global capillary collapse withrestrained rats using a tail-cuff sphygmomanometer
increased matrix deposition in over 25% of glomerular(UR-5000; UEDA Company, Tokyo, Japan). The sys-
surface area.tolic blood pressure for each rat was calculated as the
Peritubular capillary density was reported using a rar-average of three separate measurements at each session.
efaction score based on staining with JG-12 antibody
Renal morphology as described previously [21, 22]. To quantify capillary
rarefaction, JG-12 immunostained sections were exam-Methyl Carnoy’s fixed tissue was processed and paraf-
fin-embedded. Four-micrometer sections were stained ined through a 10  10-eyepiece grid under a 10 objec-
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Table 1. Histological assessments of glomerular damagetive. At this magnification, the grid covered an area of
at early time points
1 mm2. Each square (0.1 mm2) within the grid that con-
ETB receptor () ETB receptor () P valuetained no JG-12-positive vessels was scored. At least 50
Fibrin depositionfields in the cortex were examined on the longitudinal
Day 1 2.40.6 2.20.6 0.44section of each kidney. The minimum possible capillary
Day 3 1.80.5 1.70.6 0.74
rarefaction score was 0 and the maximum score 100, Platelet deposition
Day 1 2.30.6 2.20.6 0.66where 100 would indicate a complete absence of JG-12
Day 3 1.21.1 1.40.5 0.63positive cells.
Macrophage infiltration in glomeruli
Tubulointerstitial injury was scored semiquantitatively Day 1 3.70.9 3.50.8 0.75
Day 3 4.21.3 4.11.3 0.88on thirty cortical fields of periodic acid-Schiff-stained
Glomerular endothelial damagebiopsies using a 20 objective, as described previously
Day 1 1.71.1 1.81.1 0.85
[23]. Tubulointerstitial injury was defined as tubular dila- Day 3 2.51.4 2.81.1 0.70
tation, tubular atrophy, sloughing of tubular epithelial
cells, or thickening of the tubular basement membrane
and was scored on a scale of 0 to 4, as follows; 0  no
tubulointerstitial injury; 125% of the tubulointersti- with acute renal failure. To examine whether the lack
of ETB receptor affects glomerular thrombus formation,tium injured; 2  25 to 50% of the tubulointerstitium
injured; 3 51 to 75% of the tubulointerstitium injured; fibrin deposition was assessed in glomeruli by immuno-
fluorescence studies with samples obtained at day 1 and4  75% tubulointerstitium injured.
Osteopontin positive tubules were counted in ten ran- day 3. Semiquantitative analysis showed no difference
of fibrin deposition between group I and group II at daydomly selected cortical fields using a 10 objective.
PCNA positive tubular cells and ED-1 positive cells in 1 and at day 3 (Table 1). Rats perfused with normal goat
IgG (group III) had no fibrin deposition in glomeruli.the tubulointerstitium were counted in twenty randomly
selected cortical fields using a 20 objective. Platelet accumulation in glomeruli was also assessed
by immunostaining with platelet-specific monoclonal an-All assessments were performed in a blinded manner.
tibody, PL-1, using samples obtained one day and three
Statistical analysis days after induction of disease. Platelet aggregation was
not different between group I and group II at day 1Values were expressed as mean  SD and analyzed
by the Student t test or analysis of variance (ANOVA) and at day 3 (Table 1). No platelet accumulation was
observed in rats perfused with normal goat IgG (groupwith the Bonferroni protected least significant difference
test for multiple comparison. Nonparametric data were III).
Macrophage infiltration was evaluated by ED-1 stain-analyzed by Mann-Whitney test, when appropriate. Val-
ues were considered significant if P was 0.05. ing. TMA rats (group I and group II) showed more
macrophage infiltration in glomeruli at day 1 (3.7  0.9
and 3.5  0.8, respectively) and at day 3 (4.2  1.3
RESULTS
and 4.1  1.3, respectively) compared with control rats
Lack of ETB receptor in the kidney does not alter (group III, 1.4  0.3 at day 1 and 1.3  1.0 at day 3),
binding of the anti-glomerular endothelial cell but there was no difference in glomerular macrophage
antibody in the TMA model infiltration between group I and group II (Table 1).
To assess endothelial cell damage, we performed stain-To test if EDNRBsl rats and wild-type Wistar-Ima-
michi rats show different binding of pathogenic anti- ing with an endothelial cell-specific monoclonal anti-
body, JG-12, using samples obtained at day 1. Rats per-GEN IgG in the kidney, the biopsies obtained 24 hours
after induction of disease were stained with anti-goat fused with control goat IgG (group III) showed an intact
staining pattern of JG-12, while some of the glomeruliIgG. All the TMA rats (groups I and II) demonstrated
bright linear staining in a capillary pattern with anti-goat in TMA rats (groups I and II) showed a decrease in
staining. Semiquantification of JG-12 staining of glomer-IgG of the same intensity. The peritubular capillaries and
vessels also showed positive staining in the two groups uli suggested that TMA rats of group I and group II
showed equivalent glomerular endothelial damage (Ta-without any difference. Staining for goat IgG was nega-
tive in kidney tissues from Group III that had been ble 1). Furthermore, the number of peritubular capillar-
ies did not differ either at day 1 (capillary rarefactionperfused with normal goat IgG.
score 33.3  13.5 vs. 36.6  16.0, P  0.68) or at day 3
Lack of ETB receptor in the kidney did not affect (30.9  12.4 vs. 27.6  11.7, P  0.62).
TMA in the short term In these rats, the left unperfused kidneys were re-
moved for assessment of renal function when TMA wasThe primary manifestation of the TMA model in the
short term is massive thrombus formation in glomeruli induced. TMA rats (group I and group II) developed
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Table 2. Histological assessments of tubulointerstitial damage
at day 17 points
ETB ETB
receptor () receptor () P value
TI damage 2.50.4 2.00.5 0.01
OPN() tubules 7.54.1 2.92.0 0.01
PCNA() tubules 20.912.8 3.83.1 0.005
Macrophage infiltration 8.95.1 3.52.1 0.005
Capillary rarefaction 6.31.9 4.01.6 0.05
Abbreviations are: TI, tubulointerstitial; OPN, osteopontin; PCNA, proliferat-
ing cell nuclear antigen.
and V) were marked atrophy or dilatation of tubules
and interstitial fibrosis. The tubulointerstitial injury was
particularly severe in rats of group IV (Fig. 1). Semiquan-
titative analysis confirmed more severe tubulointerstitial
damage in rats of group IV compared with that in rats
of group V (Table 2). Furthermore, immunohistological
analysis employing osteopontin as a marker of tubular
injury demonstrated more osteopontin-positive tubules
in rats of group IV compared with that of group V (Fig.
2 and Table 2). Quantitative analysis of tubular cell pro-
liferation showed more PCNA-positive tubular cells in
rats of group IV compared with group V (Table 2).Fig. 1. Persistent tubulointerstitial damage in thrombotic microangi-
Macrophage infiltration in tubulointerstitium was moreopathy (TMA) rats at day 17. ETB receptor-deficient TMA rats showed
severe tubulointerstitial damage (A) compared to wild-type TMA rats severe in group IV rats compared with those of group
(B) at day 17 (PAS, 200).
V (Table 2). This was associated with more severe renal
dysfunction in EDNRBsl rats than in wild-type Wistar-
Imamichi rats at day 17 (BUN levels 72.7  23.9 vs.
acute kidney failure [blood urea nitrogen (BUN) levels 50.7  20.2 mg/dL, P  0.05). No renal dysfunction or
58.3 15.2 mg/dL and 49.4 11.7 mg/dL at day 1; 94.6 histological damage was observed in control EDNRBsl
42.7 mg/dL and 83.5  54.1 mg/dL at day 3]. There was
rats (group VI, BUN levels 25.1  5.1 mg/dL).no difference in the degree of kidney failure between
In contrast, no significant difference in glomeruli wasthe two groups (P  0.25 and 0.68 at day 1 and day 3,
observed between the two groups of TMA rats. Glomer-respectively). Rats perfused with normal goat IgG
ular sclerosis was not different between rats of group IV(group III) had markedly lower BUN levels at day 1
and group V (3.5  2.8 vs. 3.3  3.2%, P  0.87). There(30.9  5.5 mg/dL) or at day 3 (22.0  7.2 mg/dL).
was also no difference in the number of macrophages inIn summary, ETB receptor deficiency in the kidney did
glomeruli (1.0  0.5 in group IV rats and 1.0  0.4 innot change any disease manifestations examined in this
study in the short term until day 3. group V rats, respectively; P  0.84).
ETB receptor has a protective role in the Peritubular capillary damage
tubulointerstitium in TMA in the long term
The tubulointerstitial damage in group IV rats was
While glomeruli recover from the initial TMA in this associated with more severe disruption of the peritubular
model, the characteristic manifestation later in the capillary network (Fig. 3). While capillary rarefaction
course of the disease is chronic tubulointerstitial injury
was improved at day 17 compared with day 1 and day[1, 22]. Many studies emphasized that the extent of tubu-
3, peritubular capillary loss was more severe in ETB re-lointerstitial damage correlates better with the impair-
ceptor deficient rats (group IV) than in control ratsment of renal function than the degree of glomerular
(group V; Table 2). Double staining with JG-12 anddamage [24–32]. Therefore, we examined the severity
PCNA showed rare proliferating peritubular capillaryof tubulointerstitial damage at day 17. To assess renal
endothelial cells (Fig. 3 inset), but there was no statisticalfunction, the left non-perfused kidneys were removed at
difference between the two groups (0.01 0.01 cells/mm2day 14.
The main pathologic features of TMA rats (groups IV vs. 0.01  0.01, P  NS).
Nangaku et al: ETB receptor in thrombotic microangiopathy926
Fig. 3. Disruption of the peritubular capillary network in TMA rats at
Fig. 2. Osteopontin (OPN) expression by damaged tubules in TMA day 17. JG-12 staining demonstrated greater peritubular capillary den-
rats at day 17. ETB receptor-deficient TMA rats (A) show greater sity in wild type TMA rats (B) than in ETB receptor deficient TMA
expression of the tubular injury marker, osteopontin, compared to wild rats at day 17 (A; 200). Double-staining with PCNA (black) and
type TMA rats (B). Representative OPN-positive tubules are indicated JG-12 (brown) revealed occasional proliferating peritubular capillary
by arrows (200). endothelial cells (inset, 400).
Table 3. Systolic blood pressure levelsNo blood pressure changes were observed throughout
the experimental course ETB receptor-deficient Wild-type ETB receptor
TMA rats TMA rats control ratsTo examine the changes of systemic blood pressure
Pre-study 14210 14212 1368due to lack of ETB receptor in the kidney, blood pressure Day 3 14113 14620 13920
of the experimental animals was measured before induc- Day 17 14415 14513 15210
tion of the disease, and 3 days and 17 days after the
induction of the model. We did not find any changes of
systolic blood pressure levels throughout the experimen-
dopamine-beta-hydroxylase (DBH) promoter preventstal course (Table 3).
the intestinal defect in these rats [19]. In the rescued
rats, expression of ETB receptor was not detected in theDISCUSSION kidney while ETB receptor was strongly expressed in the
A naturally occurring null mutation of the gene encod- kidney of wild-type rats [19]. This can be explained by
ing the ETB receptor in spotting lethal (sl) rats exhibit the tissue-specific promoter activity of the transgene [34]
aganglionic megacolon associated with white color [33]. and enabled us to utilize rats that lack expression of ETB
These deficits result from failure of the neural crest- receptor in a tissue specific manner.
derived epidermal melanoblasts and enteric nervous sys- Rats without ETB receptor in the kidney developed
tem precursors to completely colonize the skin and intes- glomerular TMA essentially similar to that observed in
tine, respectively. Homozygous animals die within 35 rats with ETB receptor at earlier time points. In contrast,
days after birth due to intestinal obstruction [33]. Trans- the tubulointerstitial injury that is observed in a late
stage of the TMA model was aggravated by ETB receptorgenic expression of the ETB receptor with the human
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deficiency. This was associated with a decline in the num- effect on endothelial cells isolated from bovine adrenal
ber of the peritubular capillaries (PTC). Although we capillaries and human umbilical vein endothelial cells
cannot rule out the possibility that the differences in the (HUVECs) via the ETB receptor [49–51]. Recently Sa-
phenotypic responses between the two groups of animals lani and colleagues showed that the angiogenic effects
could be due to the disparate genetic background, as we of endothelin-1 was additive to that of VEGF [52]. These
could not use the sl homozygous rats because of the findings provide another possibility that the severe tubu-
lethal nature, the lack of ETB receptor in the kidney may lointerstitial injury observed in ETB receptor deficient
provide an explanation for the more severe renal injury rats might be due to impaired PTC proliferation second-
observed in the transgenic animals. ary to a lack of the ETB receptor. While we could not
Among the various components making up the tubulo- detect a significant difference in the number of proliferat-
interstitial regions of the kidney, peritubular capillaries ing PTC between the two groups of rats, it is possible
(PTC), which are a network of interstitial vessels, are that a difference in endothelial cell proliferation may
thought to play a major role in maintaining renal function have been present if tissue had been biopsied at an earlier
and hemodynamics. Several recent studies showed a time point.
strong correlation between the degree of loss of PTC Previous reports had emphasized a role of endothelin
and the progression renal disease [35–38]. Renal tubules, in tubulointerstitial damage [53]. Our findings, to our
especially by the proximal (S3 segments) and thick as- knowledge for the first time, suggested a protective role
cending limbs, are particularly susceptible to ischemic of ETB receptor on PTC and tubulointerstitial injury in
injury because of the low oxygen tensions and the high chronic ischemic damage. Our studies are consistent with
energy demands [39, 40]. Because PTC are essential for a critical role for the microvasculature in progressive
maintaining proper renal hemodynamics and for supply- renal disease.
ing oxygen to the entire kidney, it is possible that PTC
injury causes localized hypoxia, resulting in scarring of ACKNOWLEDGMENTS
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